Month: August 2011

The Global Treaty on mercury might include the prohibition of the metal in medicine.

The Global Mercury Treaty could include the prohibition of that metal in the medicine

Silver Spring, Maryland, on August 1, 2011/PRNewswire / – eat – Friday, July 22, 2011, the United Nations for the environment (UNEP) programme circulated a revised text for its comprehensive treaty on mercury. Defenders of mercury-free drugs felt happy to see the drugs included in the “Annex C (product with added mercury not permitted)” of the proposal of the Treaty.

The Coalition for mercury-free drugs (eat, for its acronym in English) helped to start this aggregate through efforts of defence in the negotiations that the United Nations (UN) held in Chiba, Japan, in January 2011. The President of the eat, Rev. Lisa Sykes, mother of a child diagnosed with poisoning with mercury related to a vaccine, described the way in which before the representatives of the 150 participating countries: “… unnecessary injection of mercury in pregnant women and children, as part of a vaccine or another drug, is a continuous and often unrecognised crisis”.

The Thimerosal (49.6% of mercury by weight), that still is used as a preservative in vaccines and as a sterilizer agent processes, is an unnecessary component and sometimes not shown in many vaccines. Its use is associated with neurological disorders in the development, cancer, birth defects and miscarriages. Those who have been adversely affected with the use of the Thimerosal in vaccines are the unborn and newborn babies.

Speaking to diplomats who attended the meeting of the UN in Chiba, Dr. Mark r. Geier of the eat noted: “this Treaty is to be totally effective, must be made clear that unintended exposure of humans to mercury, especially of pregnant women and children””, it will not be tolerated.

The comments of Dr. Geier were particularly well received by diplomats from the countries in development. The representatives of the eat met with the regional working groups in closed session and talked about the possibility of using 2-fenoxyetanol in vaccines and other drugs, as an alternative to the much less toxic Thimerosal.

Dr. Geier commented about the inequity of providing vaccines with reduced levels of mercury-Rich Nations, poor countries are still vaccines that contain levels dangerously high mercury: “children around the world, regardless of his place of birth or their level of income, are mercury-free vaccines.” “The practice of providing vaccines with levels low in mercury and mercury to the developed countries, while emphasis is placed on developing nations receive containing mercury-free, is clearly unjust.”

At the end of the negotiations in Chiba from diplomats from developing countries requested the Secretariat to assess the safety of mercury in drugs.

A team of scientists and members of the eat defenders will participate in the upcoming negotiation of the Treaty to be held in Nairobi, Kenya, between October 31 and November 4, 2011, to support the maintenance of this global prohibition of drugs containing mercury in the final version of the Treaty of the United Nations.

Read More

Rubió laboratories signs an agreement with AB BIOTICS for the co distribución Spain of Neurofarmagen r epilepsy.

Rubió laboratories signs an agreement with AB-BIOTICS for co-distribución in Spain of Neurofarmagen epilepsy r.

-this genetic analysis can predict the response of the patient to the drugs most commonly used in the treatment of the disease

-400,000 people suffering from epilepsy in Spain and 75-80% can be controlled with proper medication

-this disease involves 4.13% of the expenditure on health in Spain, according to data from the Spanish Foundation of neurological diseases

Barcelona, 2011-August Rubió laboratories has signed an agreement with the biotechnology company AB-BIOTICS for the co-distribución in the Spanish market of Neurofarmagen ® epilepsy, a genetic analysis that allows predict how you will answer the patient to drugs more used in the treatment of this disease.

According to statements by Carlos Rubió and Pelayo Rubió, co-directors laboratories Rubió General “ this new agreement with AB-BIOTICS will represent a significant increase in global billing at the national level and strengthens the aim of providing unique and innovative products to Spanish physicians. The introduction of Neurofarmagen ® epilepsy to the pharmaceutical market is a breakthrough in personalized medicine ”.

The contract on Neurofarmagen ® epilepsy is the second agreement of distribution between the two companies since last December, when AB-BIOTICS granted laboratories Rubió distribution exclusively in the Spanish market – and the right of preferential option for the granting of rights of distribution in exclusive for GermanyThe Netherlands, United Kingdom, Denmark, Argentina, Canada, New Zealand, Brazil and Mexico – from Neurofarmagen ® ADHD. This genetic analysis allows to know the patient response to major drugs for the treatment of the disorder with hyperactivity (ADHD) attention deficit, and help to assess the risk of developing this disease.

After the success of the first agreement between laboratories Rubió and AB-BIOTICS for the distribution of Neurofarmagen ® ADHD, it has reached a new agreement for codistribuir, on this occasion, Neurofarmagen ® epilepsy.

400,000 epileptics in Spain

Epilepsy is a neurological disease that affects approximately 400,000 Spaniards, and each year are diagnosed between 12,400 and 22,000 new cases according to the Spanish Foundation of neurological diseases study FEEN. The incidence is higher in the first years of life, especially in children aged between 6 and 14. Although it is estimated that you between 5% and 10% of the population will experience a crisis throughout his life, a 75-80% of patients achieved control their seizures with drugs.

Identify the most appropriate treatment is especially important for these patients, as controlling the crisis is essential to lead a normal life in the professional and personal. In this sense, Neurofarmagen ® epilepsy can assess, through a simple analysis of saliva, the willingness of the patient to respond to the drugs most commonly used for the treatment of epilepsy and other related disorders such as West syndrome, Lennox-Gastaut syndrome, Rasmussen syndromeLandau–Kleffner syndrome, the syndrome of tuberous sclerosis, Sturge-Weber Syndrome and Dravet syndrome.

In addition to assuming an improvement in the quality of life of the patient, analysis allows to reduce health spending. It is estimated that epilepsy is 4.13% of the budget allocated to health, according to data from the Spanish Foundation of neurological diseases corresponding to the year 2000.

About laboratories Rubió

Rubió laboratories is a family company founded in 1968 and headquartered in Castellbisbal (Barcelona), dedicated to the production, distribution, marketing and sale of medicines and health products boasts a prestigious commercial network established throughout the Spanish. A pharmaceutical company specializing in serving patients that suffer from low-prevalence diseases. Significant national growth of the company over the years has followed the challenge of international expansion. The firm currently sells various pharmaceutical specialties in many countries of America, Asia, Europe and Africa.

About AB-BIOTICS

AB-BIOTICS is a Spanish biotech company whose business is diversified into four business areas based on the research, development, protection and distribution of own and exclusive, biotechnological solutions with the Mission of improving the health and well-being of people. The company has an innovative philosophy and with an own know-how that allows you to develop cutting-edge products that contribute to the market a high added value.

AB-BIOTICS since last July is the first and only biotechnology company with headquarters in Catalonia and the second at Spain, which is listed in the Stock Exchange alternative market (aim), incorporating the segment of business expansion.

Read More

Antioxidant effect juice granada in insulin secretion and sensitivity in patients with obesity.

Antioxidant effect juice granada in insulin secretion and sensitivity in patients with obesity.

Spain, 2011-August study published recently by the research unit in Medical clinical epidemiology, Hospital de Especialidades, high specialty medical unit, National Medical Center’s Institute West and Mexican of the insurance Social.

Unit of Cardiovascular Research, Department of Physiology, Sciences of the health of the Central University of the University of Guadalajara, Guadalajara, Mexico.

Objective: To evaluate the effect of the juice of granada in insulin secretion and sensitivity in patients with obesity.

Methods: Study randomized, double blind, controlled placebo trial was carried out in 20 subjects obese, adult volunteers.

After the random allocation of the intervention, 10 patients received 120 ml of juice of granada or a placebo, in fasting during 1 month. Glucose, uric acid, creatinine, lipid profile and insulin were measured at the beginning of the study, and glucose and insulin were also measured at 30, 60, 90 and 120 minutes. The area under the curve of glucose and insulin, total insulin secretion and insulin sensitivity was calculated.

Results: There was a significant increase in weight, body mass and fat mass in the group index placebo after the intervention.

The secretion of insulin and insulin sensitivity is not changed with the administration of Pomegranate juice.

There was no significant difference in the variation of the fat mass between groups (1.1 ± 1.1% vs – 1.4 ± 3,0%, p = 0.010 and placebo groups in Grenada, respectively).

Conclusion: the administration of 1 month Pomegranate juice not modified insulin secretion and sensitivity in patients with obesity, however the group that swallowed Pomegranate juice, the natural evolution of weight gain and the fat was stopped.

Read More

VWR International, LLC, will acquire LabPartner (Shanghai) Co., Ltd.

VWR International, LLC, will acquire LabPartner (Shanghai) Co., Ltd.

Through strategic acquisition, VWR will strengthen its position in China

RADNOR, Pennsylvania, August 4, 2011/PRNewswire / – VWR International, LLC, a global leader in the distribution of supplies and laboratory services, announced today that it will acquire LabPartner (Shanghai) Co., Ltd., depending on the usual terms of closure and the approval of regulators chinas.

LabPartner, based in Shanghai, is an established supplier of laboratory equipment, reagentes, consumer goods and services for research and development. LabPartner supports biopharmaceutical and pharmaceutical industries in China, with primera products and integrated services, with a focus on the distribution of chemical products.

As part of the overall corporate strategy of VWR, the company is seeking opportunities to expand its international presence through selected acquisitions and the expansion of its current operations. LabPartner infrastructure will complement the current presence of VWR at the Asia Pacific region to respond to the needs of local and international customers.

“LabPartner for VWR acquisition strengthens our position in China to increase our scale, our geographic scope and offers of the supplier to our customers,” said Eddy Wu, Senior Vice President of VWR and President of Asia Pacific. “We are excited to add supplementary LabPartner business to global distribution and supply of VWR laboratory products business.”

The financial details of this acquisition are kept as confidential.

About VWR International, LLC

VWR International, LLC, headquartered in Radnor, Pennsylvania, is a global company supplies and distribution for laboratories, with worldwide sales that exceeded the $3,600 million in 2010. VWR enables the progress of most critical investigations of the world through the distribution of a highly diversified product line to the majority of pharmaceutical companies and biotechnology most important in the world, as well as industrial, educational and governmental organizations. With more than 150 years of industry experience, VWR offers a network of well-established distribution reaching thousands of laboratories and facilities specialized in the world. VWR has more than 7,000 associates around the world, working to streamline the way in which researchers in North America, Europe and Asia have and maintain their labs. In addition, VWR provides additional support to its customers by offering on-site services, warehouse management, purchase of products, supply chain systems integration and technical services.

For more information on VWR, call 1-800-932-5000, visit www.vwr.com, or write to VWR, Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road, Radnor, PA 19087.

VWR and design are registered trademarks of VWR International, LLC.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips